HUTCHMED (China) Limited
HCMHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong,. The $1.86B market capitalization puts HCM squarely in small-cap range for its industry. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Market Cap
$1.86B
Beta
0.43
P/E (TTM)
4.39
P/E (Fwd)
29.83
EPS (TTM)
$2.47
EPS (Fwd)
$0.36
ROE
45.3%
ROA
-1.6%
Cash
$1.37B
Total Debt
$97.9M
Free CF
-$54.0M
52W Change
-38.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $1.37B in cash comfortably exceeding the $97.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$54.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 45.2% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $426.4M to $548.5M.
With a beta below 0.7, HUTCHMED (China) Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, HCM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence HUTCHMED (China) Limited's trajectory.